Drug intelligence / Profile preview

4-aminosalicylic acid

Development stage: Phase 2
Lead developer: Lucane Pharma
Modality: Small Molecules
Administration: Oral

Overview

4-Aminosalicylic acid is an anti-mycobacterial agent used primarily in the treatment of tuberculosis, particularly in cases of drug-resistant TB. It acts by competing with para-aminobenzoic acid (PABA) for enzymes involved in folate synthesis, thereby inhibiting the growth of *Mycobacterium tuberculosis*. It is also used in the treatment of inflammatory bowel diseases like ulcerative colitis, though its use in this area has been largely superseded by other drugs.

Brand names: GranupasPaser
Other names: 4-amino-2-hydroxybenzoic acidp-aminosalicylic acidpara-aminosalicylic acid

Targets

MtbDHFR (Mycobacterium tuberculosis dihydrofolate reductase)PGHS-1 (Prostaglandin G/H Synthase 1)ALOX5 (Arachidonate 5-lipoxygenase)DHPS (Dihydropteroate synthase)IKK complex

Beyond the preview

Go deeper on 4-aminosalicylic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-aminosalicylic acid.

Explore the full profile